Safety and clinical efficacy of IOA-289, a novel autotaxin inhibitor, plus gemcitabine and nab-paclitaxel (GnP) in patients with previously untreated metastatic pancreatic ductal adenocarcinoma (mPDAC)

被引：0
|
作者：
Melisi, Davide
Quinzii, Alberto
Valente, Monica
Di Giacomo, Anna Maria
Amato, Giovanni
Simonetti, Elena
Zecchetto, Camilla
Casallino, Simona
Leta, Luigi
Messineo, Luisa
Mendo, Lucia
Hammett, Tracey
Deken, Marcel
Di Conza, Giusy
Kaur, Paramjit
Lahn, Michael M. F.
Maio, Michele
机构：
[1] Univ Verona, Verona, Italy
[2] Azienda Osped Univ Integrata, Verona, Italy
[3] Azienda Osped Univ Integrata, Invest Canc Therapeut Clin Unit, Verona, Italy
[4] Univ Hosp Siena, Ctr Immunooncol, Siena, Italy
[5] Univ Siena, Siena, Italy
[6] Azienda Osped Univ Senese, UOC Immunoterapia Oncol, Siena, Italy
[7] Azienda Osped Univ Integrata, Med Oncol Unit, Verona, Italy
[8] AOUI Verona, Dept Med, Digest Mol Clin Oncol Res Unit, Verona, Italy
[9] Univ Verona, Scuola Specializzaz Oncol Med, Verona, Italy
[10] iOnctura SA, Geneva, Switzerland
[11] iOnctura BV, Amsterdam, Netherlands
[12] iOnctura, Geneva, Switzerland
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15130
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Clinical outcomes of second-line chemotherapy after progression on nab-paclitaxel plus gemcitabine in patients with metastatic pancreatic adenocarcinoma
    Ha, J.
    Bang, K.
    Yoo, C.
    Jeong, J.
    Chang, H-M.
    Oh, D.
    Song, T. J.
    Park, D. H.
    Lee, S. S.
    Lee, S. K.
    Kim, M-H.
    Park, J-H.
    Kim, K-P.
    Ryoo, B-Y.
    ANNALS OF ONCOLOGY, 2019, 30
  • [42] Efficacy and safety of sintilimab combined nab-paclitaxel and gemcitabine as first-line treatment for metastatic pancreatic ductal adenocarcinoma (PDAC): A retrospective analysis
    Wang, J.
    He, Y.
    Lv, H.
    Chen, B.
    Nie, C.
    Xu, W.
    Zhao, J.
    Zhang, B.
    Cheng, X.
    Li, Q.
    Tu, S.
    Chen, X.
    ANNALS OF ONCOLOGY, 2022, 33 : S247 - S247
  • [43] Clinical Outcomes of Second-Line Chemotherapy after Progression on Nab-Paclitaxel Plus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma
    Lee, Kyoungmin
    Bang, Kyunghye
    Yoo, Changhoon
    Hwang, Inhwan
    Jeong, Jae Ho
    Chang, Heung-Moon
    Oh, Dongwook
    Song, Tae Jun
    Park, Do Hyun
    Lee, Sang Soo
    Lee, Sung Koo
    Kim, Myung-Hwan
    Park, Jin-Hong
    Kim, Kyu-Pyo
    Ryoo, Baek-Yeol
    CANCER RESEARCH AND TREATMENT, 2020, 52 (01): : 254 - 262
  • [44] Napabucasin plus nab-paclitaxel with gemcitabine in patients (pts) with metastatic pancreatic adenocarcinoma (mPDAC): Results from the phase III CanStem111P study
    Bekaii-Saab, T.
    Okusaka, T.
    Goldstein, D.
    Oh, D-Y.
    Ueno, M.
    Ioka, T.
    Fang, W.
    Anderson, E. C.
    Noel, M. S.
    Reni, M.
    Choi, H. J.
    Goldberg, J.
    Oh, S. C.
    Li, C-P.
    Tabernero, J.
    Li, J.
    Foos, E.
    Oh, C.
    Van Cutsem, E.
    ANNALS OF ONCOLOGY, 2021, 32 : S1084 - S1085
  • [45] A phase Ib study of cancer stem cell (CSC) pathway inhibitor BBI-608 in combination with gemcitabine and nab-paclitaxel (nab-PTX) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC).
    Shahda, Safi
    El-Rayes, Bassel F.
    O'Neil, Bert H.
    Starodub, Alexander
    Hanna, Wahid Tewfik
    Borodyansky, Laura
    Oh, Cindy
    Li, Chiang
    Bekaii-Saab, Tanios S.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [46] Phase 1b/2 trial of cancer stemness inhibitor napabucasin (NAPA) plus nab-paclitaxel (nPTX) and gemcitabine (Gem) in metastatic pancreatic adenocarcinoma (mPDAC).
    Bekaii-Saab, Tanios S.
    Starodub, Alexander
    El-Rayes, Bassel F.
    Shahda, Safi
    O'Neil, Bert H.
    Noonan, Anne M.
    Shaib, Walid Labib
    Hanna, Wahid Tewfik
    Mikhail, Sameh
    Neki, Anterpreet S.
    Chang, Yue
    Dai, Xiaoshu
    Li, Wei
    Brooks, Emily
    Oh, Cindy
    Borodyansky, Laura
    Li, Chiang
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [47] Randomized phase 2 study of PEGPH20 Plus nab-paclitaxel/gemcitabine (PAG) vs AG in patients (Pts) with untreated, metastatic pancreatic ductal adenocarcinoma (mPDA)
    Hingorani, S. R.
    Bullock, A.
    Seery, T.
    Zheng, L.
    Sigal, D.
    Ritch, P. S.
    Braiteh, F. S.
    Zalupski, M.
    Bahary, N.
    Harris, W.
    Pu, J.
    Aldrich, C.
    Khelifa, S.
    Wu, W.
    Chondros, D.
    Jiang, P.
    Hendifar, A.
    ANNALS OF ONCOLOGY, 2017, 28
  • [48] HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab- Paclitaxel/Gemcitabine Versus Nab- Paclitaxel/Gemcitabine in Patients With Untreated, Metastatic Pancreatic Ductal Adenocarcinoma
    Hingorani, Sunil R.
    Zheng, Lei
    Bullock, Andrea J.
    Seery, Tara E.
    Harris, William P.
    Sigal, Darren S.
    Braiteh, Fadi
    Ritch, Paul S.
    Zalupski, Mark M.
    Bahary, Nathan
    Oberstein, Paul E.
    Wang-Gillam, Andrea
    Wu, Wilson
    Chondros, Dimitrios
    Jiang, Ping
    Khelifa, Sihem
    Pu, Jie
    Aldrich, Carrie
    Hendifar, Andrew E.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04) : 359 - +
  • [49] Randomized phase II study of PEGPH20 plus nab-paclitaxel/gemcitabine (PAG) vs AG in patients (Pts) with untreated, metastatic pancreatic ductal adenocarcinoma (mPDA).
    Hingorani, Sunil R.
    Bullock, Andrea J.
    Seery, Tara Elisabeth
    Zheng, Lei
    Sigal, Darren
    Ritch, Paul S.
    Braiteh, Fadi S.
    Zalupski, Mark
    Bahary, Nathan
    Harris, William Proctor
    Pu, Jie
    Aldrich, Carrie
    Khelifa, Sihem
    Wu, Xionghua W.
    Baranda, Joaquina
    Jiang, Ping
    Hendifar, Andrew Eugene
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [50] Efficacy of SBP-101, in combination with gemcitabine and nab-paclitaxel, in first-line treatment of metastatic pancreatic ductal adenocarcinoma
    Kotasek, Dusan
    Nagrial, Adnan
    Lumba, Sumit
    Tebbutt, Niall C.
    George, Thomas J.
    Smith, Sheri Lynn
    Gagnon, Suzanne
    Cullen, Michael T.
    Walker, Michael J.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
12345